New weekly drug aims to fix Chemo-Induced low platelets
NCT ID NCT06759636
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called romiplostim N01, given as a weekly shot, against a standard daily shot (rhIL-11) for cancer patients whose platelet counts drop due to treatment. About 88 adults with various cancers and low platelets will be randomly assigned to one of the two drugs. The main goal is to see which drug raises platelet counts faster and more safely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Romiplostim N01 (a platelet-boosting drug)
What this could lead to
If it works, this could offer a more effective and convenient weekly injection to manage low platelets caused by cancer therapy.
What could go wrong
This is a relatively small Phase 3 trial (88 people), and the drug may not prove superior to the existing daily injection. Risks include potential side effects like bone marrow changes or blood clots.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CTIT: CANCER THERAPY INDUCED THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital with Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact